Social Media Newsroom
About
Contraflu PTE LTD is the developer of Cont®aFlu, a breakthrough patent-protected product for self-treatment of flu and influenza-like illness. This is the first and only product for viral infections that regulates innate host response and thus has no issue of drug resistance. The company has accumulated preclinical and clinical (Notation 10) data sufficient to perform the pivotal clinical trial and register Cont®aFlu in the EU.
Connect
Press Contact
- Name
- Andrey Martyushev-Poklad
- Phone
- +1-201-754-1864
- Contact Us
- Website
- https://www.contraflu.com
Press Releases
Contraflu Raises Funds to Run Pivotal Clinical Trial for Product to Target Drug-Resistant Influenza
×
Volume Pricing
We know many of you need to send dozens or even hundreds of press releases each month for your clients or your company, and we allow multiple newsrooms so you can manage multiple clients. We also do offer volume pricing for clients who can commit to a specific number of press releases each month.
NOTE: This is for our core distribution service and NOT the US National distribution plan.
The core distribution service goes to Google News, Twitter, DigitalJournal.com and ~150+ news and TV websites (See sites).
If you are looking to send 10 or more Releases per month, please fill out the form below to contact us
